8-K: Liminatus Pharma Regains Nasdaq Bid Price Compliance

Liminatus Pharma announced it has regained compliance with Nasdaq's minimum bid price rule following a reverse stock split and a period of sustained share price increase.

Summary

• Liminatus Pharma has successfully regained compliance with Nasdaq's minimum bid price rule.
• The company was previously notified on January 15, 2026, for failing to maintain a closing bid price of $1.00 for 30 consecutive business days.
• Following a transfer to The Nasdaq Capital Market and an extension, the company implemented a 1-for-50 reverse stock split on August 20, 2026.
• From August 21, 2026, to September 9, 2026, the closing bid price remained above $1.00 for 13 consecutive trading days.
• Nasdaq confirmed compliance on September 24, 2026, closing the matter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating the company has successfully addressed a critical compliance issue, though the underlying reasons for the initial non-compliance and the reverse stock split suggest ongoing challenges.

Positives

• Regained compliance with Nasdaq's minimum bid price rule, ensuring continued listing on the exchange.
• Successfully maintained a closing bid price above $1.00 for 13 consecutive trading days.
• The company's common stock and warrants continue to trade on The Nasdaq Stock Market.

Negatives

• The company was initially non-compliant with Nasdaq's minimum bid price rule, necessitating corrective actions.
• A 1-for-50 reverse stock split was required to meet the bid price requirement, which can sometimes be perceived negatively by investors.
• The initial notice of non-compliance was received on January 15, 2026, indicating a prolonged period of share price weakness.

Risks

• Continued listing on Nasdaq is subject to ongoing compliance with all applicable rules, including the bid price requirement.
• The company operates in a highly competitive industry with risks of downturns, new entrants, and a changing regulatory landscape.
• Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company's forward-looking statements are subject to risks and uncertainties, and there is no guarantee of future results. The company undertakes no obligation to publicly update these statements.

Management Comments

• Liminatus Pharma, Inc. (Nasdaq: LIMN) (Liminatus or the Company) today announced that the Company has regained compliance with Nasdaqs minimum bid price rule.

Industry Context

StockSavvy.ai notes that regaining compliance with listing rules is crucial for smaller biotechnology companies, especially those in the immuno-oncology and cell therapy space, as it maintains investor confidence and access to capital markets.

Stakeholder Impact

• Shareholders: Regaining compliance reduces the immediate risk of delisting, which is positive for shareholder value. However, the reverse stock split may have implications for share price perception and liquidity.
• Creditors: Continued listing on Nasdaq provides a more stable environment for the company's operations and its ability to meet financial obligations.
• Employees: Maintaining Nasdaq listing supports business continuity and employee morale.

Next Steps

• Continue to monitor compliance with Nasdaq listing rules.
• Advance the company's immuno-oncology and cell therapy candidates, including IBA101 and IBC101.

Key Dates

Recommendation

The company has successfully addressed a critical listing compliance issue, which is a positive step. However, the need for a reverse stock split and the ongoing challenges inherent in the biotechnology sector, particularly in immuno-oncology and cell therapy development, warrant a cautious 'hold' recommendation until further progress in pipeline development and sustained financial performance are demonstrated.

Keywords

Nasdaq compliance, minimum bid price, reverse stock split, biotechnology, immuno-oncology, cell therapy, Nasdaq Capital Market, listing rule